Fresh analysis indicates that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Published data in a prominent medical journal points out that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users purchasing such drugs must be cognizant of the potential of quick rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
This pace of recovery means a return to starting mass within about a year and a half.
Weighing Treatments
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with conventional dieting.
Scientists point out that individuals who shed pounds through lifestyle changes alone typically see a slower creep back—approximately 100 grams monthly—once they finish.
The Reason for the Fast Regain
Experts suggest the way of the drugs explains the accelerated regain.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating a significant risk."
A Lifelong Condition?
Medical guidelines recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts contend that, given the high risk of relapse, the treatment might need to be life-long.
This perspective is supported by drug manufacturers, who say that the findings "emphasize the persistent character of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Users who have come off the jabs describe a intense return of cravings.
"It felt as if a trigger activating and I was suddenly extremely hungry," said a patient.
This challenge is worsened if users have not developed permanent dietary or behavioural changes during treatment.
Widespread Interest
Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is greater among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and maintained weight loss hinges on combined behavioural support.
